|

CTA101 Clinical Trials

1 actively recruiting trial

Also known as: CTA101 UCAR-T cell injection

Pipeline

Early 1: 1

Top Sponsors

  • He Huang1

Indications

  • Non-hodgkin Lymphoma1
  • Acute Lymphoblastic Leukemia1
  • Cancer1

Other1 trial

A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy
Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.